Changing the History of Prostate Cancer with New Targeted Therapies

Changing the History of Prostate Cancer with New Targeted Therapies

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) is changing due to the emergence of new targeted therapies for the treatment of different molecular subtypes. Some biomarkers are described as potential molecular targets different from classic androgen receptors (A...

Full description

Bibliographic Details
Main Authors: Susana Hernando Polo, Diana Moreno Muñoz, Adriana Carolina Rosero Rodríguez, Jorge Silva Ruiz, Diana Isabel Rosero Rodríguez, Felipe Couñago
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Biomedicines
Subjects:
prostate cancer
hormonal therapy
targeted therapy
PARP inhibitors
immunotherapy
PSMA
Online Access:https://www.mdpi.com/2227-9059/9/4/392

Internet

https://www.mdpi.com/2227-9059/9/4/392

Similar Items